Business Wire
BEACON Consortium Launches to Strengthen Rigour, Reproducibility, and Real-World Impact of Scientific Research
📈
AI Sentiment
Highly Positive
9/10
- Home
- PGEN
PGEN
Precigen Inc.
as of 02-24-2026 9:38am EST
$4.17
+$0.11
+2.79%
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | GERMANTOWN |
| Market Cap: | 1.6B | IPO Year: | 2013 |
| Target Price: | $7.67 | AVG Volume (30 days): | 3.8M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.36 | EPS Growth: | -20.51 |
| 52 Week Low/High: | $1.11 - $5.46 | Next Earning Date: | 01-01-0001 |
| Revenue: | $230,981,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 342.78% | Revenue Growth (next year): | 478.46% |
| P/E Ratio: | -3.00 | Index: | N/A |
| Free Cash Flow: | -76757000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Precigen Inc. (PGEN)
KIRK RANDAL J
Sell
Director, 10% Owner
PGEN Dec 22, 2025
Avg Cost/Share
$4.18
Shares
1,900,036
Total Value
$7,942,150.48
Owned After
4,598,044
KINDLER JEFFREY B
Sell
Director
PGEN Dec 12, 2025
Avg Cost/Share
$3.63
Shares
235,467
Total Value
$855,899.00
Owned After
110,603
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| KIRK RANDAL J | PGEN | Director, 10% Owner | Dec 22, 2025 | Sell | $4.18 | 1,900,036 | $7,942,150.48 | 4,598,044 | |
| KINDLER JEFFREY B | PGEN | Director | Dec 12, 2025 | Sell | $3.63 | 235,467 | $855,899.00 | 110,603 |
Latest Precigen Inc. News
PGEN Breaking Stock News: Dive into PGEN Ticker-Specific Updates for Smart Investing
Business Wire
RAD Intel Launches RAD Amplify as Standalone Operating Company
📈
AI Sentiment
Highly Positive
9/10
MT Newswires
UBS Adjusts Price Target on PPL to $41 From $38, Maintains Neutral Rating
📊
AI Sentiment
Positive
7/10
MT Newswires
UBS Adjusts Price Target on Chemours Co to $23 From $18, Maintains Buy Rating
📊
AI Sentiment
Positive
6/10
MT Newswires
Cloudflare Adds Post-Quantum Encryption to All Major Network Configurations
📊
AI Sentiment
Positive
7/10
PR Newswire
Royal® Unveils Refreshed Jute Bag Design for 20lb Authentic Basmati
📈
AI Sentiment
Highly Positive
9/10
MT Newswires
Globex Mining Says East Nordeau Zone on Royalty Claims Returns High-Grade Gold Drill Results
âž–
AI Sentiment
Neutral
5/10
Compare PGEN vs Leading Stocks
See how PGEN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PGEN Precigen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.